- Home
- CDXS vs SCPH Comparison
CDXS vs SCPH Comparison
Compare CDXS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- SCPH
- Stock Information
- Founded
- CDXS 2002
- SCPH 2013
- Country
- CDXS United States
- SCPH United States
- Employees
- CDXS N/A
- SCPH N/A
- Industry
- CDXS Major Chemicals
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- SCPH Health Care
- Exchange
- CDXS Nasdaq
- SCPH Nasdaq
- Market Cap
- CDXS 201.3M
- SCPH 173.6M
- IPO Year
- CDXS 2010
- SCPH 2017
- Fundamental
- Price
- CDXS $2.43
- SCPH $3.92
- Analyst Decision
- CDXS Buy
- SCPH Strong Buy
- Analyst Count
- CDXS 2
- SCPH 3
- Target Price
- CDXS $11.00
- SCPH $14.00
- AVG Volume (30 Days)
- CDXS 791.1K
- SCPH 289.6K
- Earning Date
- CDXS 08-07-2025
- SCPH 08-13-2025
- Dividend Yield
- CDXS N/A
- SCPH N/A
- EPS Growth
- CDXS N/A
- SCPH N/A
- EPS
- CDXS N/A
- SCPH N/A
- Revenue
- CDXS $49,815,000.00
- SCPH $41,982,000.00
- Revenue This Year
- CDXS $12.77
- SCPH $108.95
- Revenue Next Year
- CDXS $22.12
- SCPH $73.83
- P/E Ratio
- CDXS N/A
- SCPH N/A
- Revenue Growth
- CDXS N/A
- SCPH 138.10
- 52 Week Low
- CDXS $1.90
- SCPH $1.94
- 52 Week High
- CDXS $6.08
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- CDXS 51.66
- SCPH 57.14
- Support Level
- CDXS $2.32
- SCPH $3.77
- Resistance Level
- CDXS $2.58
- SCPH $4.03
- Average True Range (ATR)
- CDXS 0.14
- SCPH 0.19
- MACD
- CDXS 0.02
- SCPH -0.06
- Stochastic Oscillator
- CDXS 59.76
- SCPH 31.82
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.